TARO Taro Pharmaceutical Industries
- 42.390
- -0.090-0.21%
- 42.390
- 0.0000.00%
Taro Pharmaceutical Industries News
Taro Pharmaceutical: If Merger Is Completed, Taro Will Become a Privately Held Co >TARO
Taro Pharmaceutical: If Merger Is Completed, Taro Will Become a Privately Held Co >TARO
Express News | Taro Announces Extraordinary General Meeting and Ordinary Class Meeting of Shareholders for Approval of Merger With Sun Pharmaceutical Industries Ltd.
Taro Announces Extraordinary General Meeting And Ordinary Class Meeting Of Shareholders For Approval Of Merger With Sun Pharmaceutical Industries Ltd. >TARO
Taro Announces Extraordinary General Meeting And Ordinary Class Meeting Of Shareholders For Approval Of Merger With Sun Pharmaceutical Industries Ltd. >TARO
Taro Pharmaceuticals U.S.A., Inc. Expands OTC Portfolio for Children With the Introduction of Bébé Bottoms Diaper Rash Crème Spray
Made with TLC – Thin Layer Care Technology, New bébé Bottoms Diaper Rash Crème Spray Combines Zinc Oxide (10%) with Soothing Chamomile and Calendula in a Convenient, No-Touch Spray Application HAW
Estée Lauder, Reckitt Fall Amid Cancer Risk in Acne Treatments
Krensavage Asset Management Remains Opposed to Sun's Predatory Bid for Taro
Taro Pharmaceutical Industries Fiscal Q3 Net Income, Net Sales Rise; Shares Climb After Hours
Taro Pharmaceutical Industries (TARO) reported fiscal Q3 net income Thursday of $0.54, up from $0.19 a year earlier. A lone analyst polled by Capital IQ expected $0.30. Net sales in the quarter ended
Express News | Taro Pharmaceutical Indus Q3 2024 GAAP EPS $0.54 Beats $0.30 Estimate
Taro Pharmaceutical Inds 3Q Sales $157.1M >TARO
Taro Pharmaceutical Inds 3Q Sales $157.1M >TARO
Press Release: Taro Provides Results for December 31, 2023
Taro Provides Results for December 31, 2023 HAWTHORNE, N.Y.--(BUSINESS WIRE)--January 25, 2024-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") today provided unaudited f
Earnings Scheduled For January 25, 2024
Companies Reporting Before The Bell • Nokia (NYSE:NOK) is projected to report quarterly earnings at $0.15 per share on revenue of $7.05 billion. • Popular (NASDAQ:BPOP) is likely to report quarterly e
Taro Pharmaceutical Q3 2024 Earnings Preview
Notable Earnings After Thursday's Close
Earnings Preview For Taro Pharmaceutical Indus
Taro Pharmaceutical Indus (NYSE:TARO) is set to give its latest quarterly earnings report on Thursday, 2024-01-25. Here's what investors need to know before the announcement.Analysts estimate that Tar
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Taro Pharmaceutical Industries Ltd. Buyout
Wilmington, Delaware--(Newsfile Corp. - January 24, 2024) - Rigrodsky Law, P.A. is investigating Taro Pharmaceutical Industries Ltd. ("Taro") (NYSE: TARO) regarding possible breaches of fiduciary duti
Taro to Release Third Quarter Results on January 25, 2024
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the third quarter ended December 31, 2023, after the close of market on Thursday, January 25,
Taro Pharmaceutical Inds Cut to Neutral From Buy by HC Wainwright & Co.
Taro Pharmaceutical Inds Cut to Neutral From Buy by HC Wainwright & Co.
Express News | HC Wainwright & Co. Downgrades Taro Pharmaceutical Indus to Neutral, Maintains Price Target to $43
Taro Pharmaceutical Indus Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 01/18/2024 3.12% HC Wainwright & Co. $43 → $43 Downgrades Buy → Neutral 01/25/2023 -16.07% HC Wainwright &
Taro Pharmaceutical to Go Private in Merger Deal With Sun Pharmaceutical
Taro Pharmaceutical Industries' (TARO) has agreed to an acquisition by its controlling shareholder Sun Pharmaceutical Industries, the companies said Wednesday. Sun has agreed to buy all Taro shares it
Analysis
Price Target
No Data
